Molecular markers (c-erbB-2, p53) in breast cancer

Folia Histochemica et Cytobiologica

Volumn 46, Issue 4, 2008, Pages 449-455

  Agrawal, Anil Kumar ^a   Jeleń, Michał ^a   Rudnicki, Jerzy ^a   Grzebieniak, Zygmunt ^a   Zukrowski, Piotr ^a   Nienartowicz, Ewa ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Breast cancer; C erbB 2; Molecular markers; p53

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN P53; CANCER ANTIBODY; ERBB2 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER GROWTH; CANCER STAGING; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MASTECTOMY; POSTMENOPAUSE; PREMENOPAUSE; PROGNOSIS; PROTO ONCOGENE; TUMOR VOLUME; BREAST TUMOR; IMMUNOLOGY; METABOLISM; MIDDLE AGED; RADIOGRAPHY;

ADULT; AGED; ANTIBODIES, NEOPLASM; BREAST NEOPLASMS; FEMALE; HUMANS; MAMMOGRAPHY; MIDDLE AGED; RECEPTOR, ERBB-2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 60549108888     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10042-008-0059-7     Document Type: Article

References (55)

1. Parkin DM. International variationtion. Oncogene. 2004;23: 6329-6340.
2. Stewart SL, King JB, Thompson TD, Friedman C, Wingo PA. Cancer mortality surveillance - United States 1990 - 2000. MMWR Surveill Summ. 2004;53:1-108.
3. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connoly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ. Prognostic factors in breast cancer. College of American Pathologist Consensus Statement 1999. Arch Pathol Lab Med. 2000;124:966-978.
4. Warnberg F, Nordgren H, Bergkvist L, Holmberg L. Tumor markers in breast canser correlate with grade rather than with invasiveness. Br J Cancer. 2001;85:869-874.
5. Zaslawski R, Surowiak P, Paluchowski P, Dziegiel P, Maciejczyk A, Pudelko M, Wojnar A, Zabel M. Differences in oestrogen and progesterone receptors, HER-2 and p53 expresion and proliferation in ductal breast cancers in relation to histopathological. Folia Morphol. 2005;64(1):9-14.
6. Dimitrakakis C, Konstadoulakis M, Messaris E, Kymionis G, Karayannis M, Panoussopaulos D, Michalas S, Androulakis G. Molecular markers in breast cancer: can we use c-erbB-2, p53, bcl-2 and bax gene expression as prognostic factors? Breast. 2002;11(4):279-285.
7. Dumitrescu RG, Cotarla I. Understanding breast cancer risk - where do we stand in 2005? J Cell Mol Med. 2005;9(1):208-221.
8. Hulka BS, Moorman PG. Breast cancer: hormones and other risk factors. Maturitas. 2001;38:103-113.
9. Huang HJ, Neven P, Drijkoningen M, Paridaens R, Wildiers H, Limbergen EV, Berteloot P, Amant F, Christiaens MR, Vergote I. Association between HER-2/neu and progesteron receptor in oestrogen-dependent breast cancer. Breast Cancer Res Treat. 2005;91(1):81-87.
10. Parkin DM, Pisarini P, Ferlay J. Global cancer statistics. CA Cancer J Clin. 1999;49:33-64.
11. Simpson JF, Page DL. The role of pathology in premalignancy and as a guide for treatment and prognosis in breast cancer. Semin Oncol. 1996;23(4):428-435.
12. Zatośki J, Tyczyński N. Malignant neoplasms in Poland (Nowotwory złośliwe w Polsce w 1991 r.) Center of Oncology, Warsaw 1994.
13. Tsakuntakis N, Sanidas E, Stathopoulos E, Kafousi M, Angiannaki N, Georgaulias V, Tsiftsis DD. Correlation of breast cancer risk factors with HER-2/neu protein overexpression according to menopausal and estrogen receptor status. BMC Womens Health. 2005;5(1):1.
14. Ciocca DR, Fujimura FK, Tandon AK, Clark GM, Mark C, Lee-Chen GJ. Pouns GW, Vendely P, Owens MA, Pandian MR. Correlation of HER-2/neu amplification with expression and with other prognostic factors in 1103 breast cancers. J Natl Cancer Inst. 1992;84:1279-1282.
15. Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, Kobayashi S, Iwase H. Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer. Breast Cancer Res. 2004;6(1): R24-30.
16. Huang WY, Newman B, Millikan RC, Conway K, Hulka BS, Schell MJ, Liu ET. Risk of breast cancer according to the status of HER-2/neu oncogene amplification. Cancer Epidemiol Biomarkers Prev. 2000;9:65-71.
17. Callahan R. Genetic alterations in primary breast cancer. Breast Cancer Res Treat. 1989;13:191-203.
18. Bokiniec-Dziewulska A, Zółtowska A, Roszkiewicz A, Ciesielski D, Kopacz A, Wojtacki J. Białko p53 a inne czynniki prognostyczne w raku sutka. Nowotwory. 1994;44:310-315.
19. May E, Mouriesse H, Levin-May F, Qian JF, May P, Delarue JC. Human breast cancer: identification of populations with a high risk of early relapse in selection of both oestrogen receptor status and c-erbB-2 overexpression. Br J Cancer. 1990;62: 430-435.
20. Tsutsui S, Ohno S, Murakam S, Hachitanda Y, Oda S. Prognostic value of p53 protein expression in breast cancer; an immunohistochemical analysis of frozen sections in 514 Japanese women. Breast Cancer. 2001;8(3):194-201.
21. Barnes DM, Hanby AM, Gillett CE. Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet. 1992;346:259-263.
22. Ali SU, Campbell G, Lidereau R, Callahan R: Amplification of c-erbB-2 and aggressive human breast tumors. Science. 1988;240:1795-1798.
23. Znou DJ, Ahuji H, Cline MT. Protooncogene abnormalities in human breast cancer. c-erbB-2 amplifications does not correlate with recurrence of disease. Oncogene. 1989;4:105-112.
24. Wright C, Angus B, Nicholson S. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res. 1989;49:2087-2090.
25. Lacroix H, Iglehart JD, Skinner MA, Kraus MH. Overexpression of c-erbB-2 or FGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. Oncogene. 1989;4:145-151.
26. Berger MS, Locher GW, Saurer S. Corelation of c-erbB-2 gene amplification and protein expression in hunam breast carcinoma with nodal status and nuclear grading. Cancer Res. 1988;48:1238-1243.
27. Guerin M, Gabillot M, Matthieu MC. Structure and expression of c-erbB-2 and EGF receptor gen in inflammatory and non-inflammatory breast cancer prognostic significance. Int J Cancer. 1989;43:201-208.
28. Wang XT. The significance of overexpression c-erbB-2, p53 in breast cancer patients prognosis in China. XVI International Cancer Congress 1994, New Delhi, India, Abstract Book nr 1, 163.
29. Hurlimann J, Chaubert P, Benhattar J. p53 Gene alterations and p53 protein accumulation in infiltrating ductal breast carcinomas: correlation between immunohistochemical and molecular biology techniques. Mod Pathol. 1994;7:423-428.
30. Kerns BJ, Jordan PA, Moore MB, Humphrey PA, Berchuck A, Kohler MF, Bast RC Jr, Iglehart JD, Marks JR. p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry. J Histochem Cytochem. 1992;40:1047-1051.
31. Momand J, Wu HH, Gasgupta G. MDM2 - master regulator of the p53 tumor supresor protein. Gene. 2000;242:15-29.
32. Colozza M, Cardoso F, Sotiriou C, Larsimont D, Piccart MJ. Correlations of cell cycle regulators (p53, p21, pRb and mdm2) and c-erbB-2 with biological markers of proliferation and overall survival in breast cancer. Pathology. 2005;37(1): 45-50.
33. Bartek J, Bartkova J, Wojtesek B, Staskova Z, Rejthar A, Kovarik J, Lane DP. Patterns of expressions of the p53 tumor suppressor in human breast tissues and tumors in situ and in vitro. Int J Cancer. 1990;46:839-844.
34. Thor AD, Moore II DH, Edgerton SM. Accumulation of p53 tumor suppressor gene protein an independent marker of prognosis in breast cancer. J Natl Cancer. 1992;84:845-855.
35. Maru D, Middleton LP, Wang S, Valero V, Sahin A. HER-2/neu and p53 overexpression as biomarkers of breast carcinoma in women age 30 years and younger. Cancer. 2005; 103(5):900-905.
36. Rosianu A, Tudose N. Correlation between p53 expression and other prognostic factors in breast cancer. Rom J Morphol Embryol. 1998;44(1-4):133-140.
37. Nakopoulou LL, Alexiadou A, Theodoropoulos GE, Lazaris AC, Tzonou A, Keramopoulos A. Prognostic significance of the co-expression of p53 and c-erbB-2 proteins in breast cancer. J Pathol. 1996;179:31-38.
38. Howard EM, Lau SK, Lyles RH, Birdsong GG, Tadros TS, Umbreit JN, Kochhar R. Correlation and expression of p53, HER-2, vascular endothelial growth factor (VEGF), and e-cadherin in a high-risk breast-cancer population. Int J Clin Oncol. 2004;9(3):154-160.
39. Korkolis DP, Tsoli E, Fouskakis D, Yiotis J, Koullias GJ, Giannopoulos D, Papalambros E, Nikiteas NI, Spiliopoulou CA, Patsouris E, Asimacopoulos P, Gorgoulis VG. Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients. Anticancer Res. 2004;24(3b):2061-2068.
40. Thompson AM, Steel CM, Chefty V. p53 gene in RNA expression and chromosome 17p allele breast cancer. Br J Cancer. 1990;61:39-45.
41. Aiello EJ, Buist DS, White E, Porter PL. Association between mammographic breast density and breast cancer tumor characteristics. Cancer Epidemiol Biomarkers Prev. 2005;14(3): 662-668.
42. Fisher ER. Pathology of breast cancer. In Breast cancer vol. 1. London - New York 1977, pp. 43-123.
43. Fehm T, Becker S, Pergola-Becker G, Kramer B, Gruber I, Sotlar K, Kurek R, Wallwiener D, Solomayer E. Influence of tumor biological factors on tumor cell dissemination in primary breast cancer. Anticancer Res. 2004;24(6):4211-4216.
44. Rosen PP, Lesser ML, Arroyo CD, Cranor M, Borgen P, Norton L. p53 in node-negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features, and prognosis. J Clin Oncol. 1995;13:821-830.
45. De la Haba-Rodriguez JR, Ruiz Borrego M, Gomez Espana A, Villar Pastor C, Japon MA, Travado P, Moreno Nogueira JA, Lopez Rubio F, Aranda Aguilar E. Comparative study of the immunohistochemical phenotype in breast cancer and its lymph node metastatic location. Cancer Invest. 2004;22(2): 219-224.
46. Climent MA, Segui MA, Peiro G, Molina R, Lerma E, Ojeda B, Lopez-Lopez JJ, Alonso C. Prognostic value of HER-2/neu and p53 expression in node-positive breast cancer. HER-2/neu effect on adjuvant tamoxifen treatment. Breast. 2001;10(1):67-77.
47. Bull SB, Ozcelik H, Pinnaduwage D, Blackstein ME, Sutherland DA, Pritchard KI, Tzontcheva AT, Sidlofsky S, Hanna WM, Qizilbash AH, Tweeddale ME, Fine S, McCready DR, Andrulis IL. The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer. J Clin Oncol. 2004;22(1):86-96.
48. Reed W, Hannisdal E, Boehler PJ, Gundersen S, Host H, Marthin J. The prognostic value of p53 and c-erbB2 immunostaining is overrated for patients with lymph node negative breast carcinoma: a multivariante analysis of prognostic factors in 613 patients with a follow-up of 14-30 years. Cancer. 2000;88:804-813.
49. Trojani M. Types histologiques de 876 cancers du sein selon le classification de l'OMS 1981. Bull Cancer (Paris). 1984; 71:65-69.
50. Lee YTN, Terry R. Surgical treatment of carcinoma of the breast. I. Pathological findings and pattern of relapse. J Surg Oncol. 1983;23:11-15.
51. Cattoretti G, Rilke F, Andreola S, D'Amato L, Delia D. p53 expression in breast cancer. Int J Cancer. 1988;41:178-183.
52. Huang WY, Newman B, Millikan RC, Conway K, Hulka BS, Schell MJ, Liu ET. Risk of breast cancer according to the status of HER-2/neu oncogene amplification. Cancer Epidemiol Biomarkers Prev. 2000;9:65-71.
53. Arpino G, Bardou VJ, Clark GM, Elledge RM. Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res. 2004;6(3):R149-R156.
54. Tsutsui S, Ohno S, Murakami S, Kataoka A, Kinoshita J, Hachitanda Y. Histological classification of invasive ductal carcinoma and the biological parameters in breast cancer. Breast Cancer. 2003;10(2):149-152.
55. Coradini D, Pellizzaro C, Veneroni S, Ventura L, Daidone MG: Infiltrating ductal and lobular breast carcinomas are characterised by different interrelationships among markers related to angiogenesis and hormone dependence. Br J Cancer. 2002;87(10):1105-1111.